Synlab AG Stock – Fundamental Analysis
Not enough price data available yet.
Fundamental Data & Ratios (Balance sheet update: 7/20/2025)
| Balance Sheet | Total Assets | 2,200,000,000.00 | ROE | – |
| Balance Sheet | Total Equity | 2,400,000,000.00 | ROA | – |
| Cashflow | Capital Expenditures | -300,000,000.00 | P/FCF | – |
| Cashflow | Free Cash Flow | 120,000,000.00 | – | – |
| Cashflow | Operating Cash Flow | 420,000,000.00 | P/CF | – |
| Income | Earnings per Share (diluted) | 2.17 | Div. Yield | – |
| Income | Net Income | 130,000,000.00 | P/E | – |
| Income | Shares Outstanding | 59,907,800.00 | P/B | – |
| Income | Total Revenue | 2,620,000,000.00 | P/S | – |
Ratios calculated on: –
Company Description
SYNLAB AG provides clinical laboratory and medical diagnostic services for practicing doctors, clinics, patients, and the pharmaceutical industry primarily in Europe. The company offers Coronavirus tests, and medical and veterinary diagnostics services. It operates through approximately 450 laboratories and 1,600 blood collection points in 36 countries in four continents. The company was founded in 1998 and is headquartered in Munich, Germany.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.synlab.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more